Truong X Q, Bakali Issaui Z, Gaillet S, Boissier R, Gondran-Tellier B, Delporte V, Lechevallier E, Karsenty G, Michel F
CCA d'urologie, service d'urologie et de transplantation rénale, hôpital de la Conception, Assistance publique des Hôpitaux de Marseille, Marseille, France.
CCA d'urologie, service d'urologie et de transplantation rénale, hôpital de la Conception, Assistance publique des Hôpitaux de Marseille, Marseille, France.
Prog Urol. 2023 Sep;33(11):547-554. doi: 10.1016/j.purol.2023.07.010. Epub 2023 Sep 4.
To determine the surgical indication and results of bladder augmentation (BA) during the last decade in a neurourology center in the era of intradetrusor botulinum toxin injection.
We conducted a retrospective study that included patients with BA between January 1, 2012 and December 31, 2022 in our centre. We collected pre-operative demographic, clinical, and urodynamic data, BA indication, and associated procedures. We analyzed early and late complications as well as continence and postoperative voiding mode in patients with first BA in a neurological pathology context.
We performed 77 BA over the study period. The main indication was neurogenic overactive bladder, which was secondarily resistant to botulinum toxin. The main associated procedure was continent cutaneous diversion (n=31, 57.4%). Among patients who had a first BA for neurogenic bladder, 34 patients had early complications (50%) including 12 patients with≥Clavien 3 complications (17.6%). After a median follow-up of 33 [14; 55] months, 23 patients had late complications (33.8%) and 59 patients had complete continence (86.8%).
In the era of botulinum toxin, the main indication of BA is the secondary failure of botulinum toxin for overactive neurogenic bladder. The BA provided continence in 86.8% of patients. It remains however an intervention with a significant rate of severe complications whose indication must be discussed by a multidisciplinary team.
Weak.
